Skip to main content

Market Overview

FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application


The FDA has issued a Refusal to File letter covering Novo Nordisk A/S' (NYSE: NVO) label expansion application for once-weekly semaglutide 2.0 mg to treat type 2 diabetes, which was filed on 20 January.

  • The FDA has requested additional information in the letter, including data relating to a proposed new manufacturing site.
  • The company will resubmit the application to FDA during the second quarter of 2021.
  • Though there is a requirement for additional information for resubmission, Novo Nordisk believes the already completed trial program will be sufficient for approval of the label expansion application.
  • Price Action: NVO shares are trading 1.59% lower at $69.92 in premarket on the last check Tuesday.

Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: Type 2 DiabetesBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at